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Hydrogen sulfide modulates chromatin
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does not play a role in the development of
endotoxin tolerance
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Abstract
Background: Pretreatment with low doses of LPS (lipopolysaccharide, bacterial endotoxin) reduces the pro-inflammatory
response to a subsequent higher LPS dose, a phenomenon known as endotoxin tolerance. Moreover, hydrogen sulfide
(H2S), an endogenous gaseous mediator (gasotransmitter) can exert anti-inflammatory effects. Here we investigated the
potential role of H2S in the development of LPS tolerance. THP1 differentiated macrophages were pretreated with the
H2S donor NaHS (1 mM) or the H2S biosynthesis inhibitor aminooxyacetic acid (AOAA, 1 mM).
Methods: To induce tolerance, cells were treated with a low concentration of LPS (0.5 μg/ml) for 4 or 24 h, and
then treated with a high concentration of LPS (1 μg/ml) for 4 h or 24 h. In in vivo studies, male wild-type and
CSE-/- mice were randomized to the following groups: Control (vehicle); Endotoxemic saline for 3 days before the
induction of endotoxemia with 10 mg/kg LPS) mg/kg; Tolerant (LPS at 1 mg/kg for 3 days, followed LPS at 10 mg/kg).
Animals were sacrificed after 4 or 12 h; plasma IL-6 and TNF-α levels were measured. Changes in histone H3 and H4
acetylation were analyzed by Western blotting.
Results: LPS tolerance decreased pro-inflammatory cytokine production. AOAA did not affect the effect of tolerance
on reducing cytokine production. Treatment of the cells with the H2S donor reduced cytokine production. Induction of
the tolerance increased the acetylation of H3; AOAA reduced histone acetylation. H2S donation increased histone
acetylation. Tolerance did not affect the responses to H2S with respect to histone acetylation.
Conclusions: In conclusion, both LPS tolerance and H2S donation decrease LPS-induced cytokine production in vitro
and modulate histone acetylation. However, endogenous, CSE-derived H2S does not appear to play a significant role in
the development of LPS tolerance.
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Background
Sepsis, a systemic inflammation caused by pathogens,
remains a significant clinical problem [1, 2]. Amongst a
multitude of pathophysiological events affecting the
cardiovascular and immune system during sepsis, the
outcome of sepsis is significantly affected by the severity
of vascular disturbances, compromising oxygen delivery
to the tissues, contributing to the development of multiple
organ dysfunction. In the early phase of sepsis and septic
shock there is an intense release of pro inflammatory
mediators that can promote tissue injury and multiple
organ dysfunction [3–7].
The induction of tolerance to lipopolysaccharide (LPS)
has been investigated for several decades as a potential
therapeutic approach for sepsis [8–18]. LPS tolerance
downregulates the inflammatory response in septic shock
while also increasing the ability of a host to eliminate the
pathogens; it exerts protective effects in several models of
sepsis and polymicrobial infection [14–18]. Inflammatory
gene silencing resulting from tolerance can persist for days
to weeks [8–10]. The mechanisms involved in LPS tol-
erance include toll-like receptor desensitization as well
as the suppression of the inflammatory signaling path-
ways that regulate the production of anti-inflammatory
cytokines, at least in part via epigenetic changes [11].
Chromatin remodeling during the period of LPS toler-
ance development modifies gene transcription profile
and regulates or silences a host of genes in response to
a subsequent challenge [12, 13]. LPS tolerance also
modulates the production of reactive oxygen and nitro-
gen species (ROS/RNS) [16].
Hydrogen sulfide (H2S) emerges as a novel gaseous
mediator and signaling molecule, with multiple roles in
health and disease [19]. Among other pathways, H2S regu-
lates the activation of ERK and p38 MAP kinase, modulates
cell proliferation and regulates oxidant-induced cell death
[19–25]. Here we investigated effect of modulation of H2S
homeostasis (by H2S donation or inhibition of endogenous
H2S generation) in in vitro/vivo models of LPS tolerance
and endotoxemia.
Methods
Macrophage culture and differentiation
THP1 monocytes obtained from ATCC were differentiated
into macrophage using 100 nM phorbol myristate acetate
(PMA) for 5 h in RPMI 1640 supplemented with 2 mM L-
glutamine, 100 U/ml penicillin, 100 μg/ml streptomycin
and 10 % fetal bovine serum (FBS) (Sigma). Ultrapure
Escherichia coli 0111:B4 LPS free of lipoproteins was
obtained from Invitrogen (San Diego, CA).
In vitro model of tolerance and sepsis
THP1 cells were plated in 22 mm tissue culture dishes
(2 × 106 cells/dish). In the first experimental design, four
groups of cells were studied (Fig. 1a). Group “C” (i.e.
“Control”) was designated as the control group that was
maintained with medium and received vehicle only. Group
“T” (i.e. “Tolerance”) received a single and low concentra-
tion of LPS at 0.5 μg/ml for 4 h, followed by washout, and
further incubation for 4 h. Group “TD” (i.e. “Tolerance +
Direct Challenge”) received the same low concentration of
LPS (0.5 μg/ml) as the “T” group, followed, at 4 h, by a
higher concentration of LPS (1 μg/ml) for an additional
4-h period. Group “D” (i.e. “Direct Challenge”) did not
receive the low concentration of LPS; instead it re-
ceived vehicle at the beginning of the experiment, but it
received the higher concentration of LPS (1 μg/ml) 4 h
later. Culture supernatant was collected 4 h after the
challenge with the higher concentration of LPS (1 μg/
ml, i.e. 8 h after the start of the experiment). In the
next set of experimental design (Fig. 1b), a similar ap-
proach was used, but the time period for both the first,
tolerizing concentration (0.5 μg/ml) and for the second,
higher (“challenge”) concentration (1 μg/ml) was ex-
tended to 24 h. In these experiments, culture super-
natant was collected 24 h after the challenge with the
higher concentration of LPS (1 μg/ml, i.e. 48 h after the
start of the experiment). Cell viability was not effected
under these experimental conditions (Fig. 2).
To study the effect of the H2S biosynthesis inhibitor
aminooxyacetic acid (AOAA) or the H2S donor NaHS,
the experimental design shown in Fig. 3a and b was
employed. The Control group (Group “C”) received 2
sets of treatment (each times 30 min) with the H2S mod-
ulators (each time, the 30 min exposure was followed by
wash-outs, prior to the subsequent application of LPS).
Since our goal was to understand the effect of H2S mod-
ulators on the development of LPS tolerance, the groups
that received the low (tolerizing) exposure to LPS
(Groups “T” and “TD”) received 30 min of treatment
with either NaHS or AOAA before the low concentration
of LPS. On the other hand, for the group designated to
serve as the “Direct Challenge” group (“DC”) by expos-
ing it to the higher concentration of LPS (group “D”) the
exposure to NaHS or AOAA was applied 30 min prior
to this very stimulus. This experimental design was
employed both in the shorter experimental design (4 h
of low concentration of LPS exposure, followed by 4 h of
high concentration of LPS exposure, followed by the col-
lection of culture supernatant at 8 h) (Fig. 3a) and in the
longer experimental design (24 h of low concentration
of LPS exposure, followed by 24 h of high concentration
of LPS exposure, followed by the collection of culture
supernatant at 48 h) (Fig. 3b).
In vivo model of tolerance and endotoxemia
All procedures were performed in accordance to the
Guide for the Care and Use of Laboratory Animals
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published by the US National Institutes of Health and
were was approved by UTMB’s IACUC. Animals were
anesthetized (i.p) with a mixture of ketamine (80 mg/kg)
and xylazine (10 mg/kg). Male C57bl/6 wild-type mice
or cystathionine γ-lyase (CSE)-deficient mice (a kind
gift of Dr. Solomon Snyder, Johns Hopkins University,
Baltimore, MD) were randomized in the following
groups: Group C (control group) - no treatment; Group
D (directly challenged/endotoxemic) – received 0.1 ml
normal saline i.p. during 3 days before the induction of
endotoxemia (LPS 10 mg/kg); Group TD (tolerant +
endotoxemic)—animals received LPS 1 mg/kg i.p. dur-
ing first 3 days before the induction of endotoxemia
(LPS 10 mg/kg). 2 ml lactated Ringer’s solution alone
i.p. was administered immediately after endotoxemia
induction. 4 or 12 h after endotoxemia induction, ani-
mals were sacrificed and plasma collected.
Cell viability
To estimate cell viability of the in vitro model of tolerance
described before 3-(4,5-dimethyl-2-thiazolyl)- 2,5-diphe-
nyl-2H-tetrazolium bromide (MTT) was added to the
cells at a final concentration of 0.5 mg/ml and cultured at
37 °C for 1 h. Cells were washed with PBS and the forma-
zan dye was dissolved in isopropanol. The amount of
converted formazan dye was measured at 570 nm with a
background measurement at 690 nm on spectrophotom-
eter (Tecan Genius, Salzburg, Austria). Viable cell count
was calculated as a percent of control cells.
Western blot analysis
THP-1 cells lysed in RIPA buffer and sonicated (3 times
of 10 s). The supernatants were preserved and protein
concentration was determined by BCA (BioRad). 25 μg
cell extract was resuspended in equal volume of loading
Fig. 1 In vitro experimental protocols of LPS tolerance used in the current study
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buffer (20 mM Tris-HCl, pH 6.8; 2 % SDS; 10 % glycerol;
6 M Urea 2 %; 15 % β-mercaptoethanol; urea 6 and
0.01 % bromophenol blue), boiled for 2 min and electro-
phoresed on 8–12 % SDS-polyacrylamide gels. After
electrophoretic separation, proteins were transferred to
PDF membranes. Membranes were blocked with T20
Starting Buffer (Thermo Scientific) for 1 h. Following
primary antibodies at the dilution 1:1,000 were used:
rabbit acetylated histone H3 at N-terminal tail (Millipore
06-599), anti-histone H4 acetylated at lysine 5/8/12/16
(Millipore 06-866), HRP conjugated β-actin (Santa Cruz
Biotechnology). The primary antibodies were incubated
overnight at 4 °C the membranes were washed twice in
TBST. A secondary horseradish-peroxidase-conjugated
antibody (goat anti-rabbit, Cell Signaling) was then
applied at a dilution of 1:5000 for 1 h. Over a 30-min
period, the blots were washed twice in TBST. Signal
was obtained using Super Signal Detection Kit (Pierce,
Rockford, IL, USA). Band intensity was quantified using
Genetools (Syngene, Synoptics Ltd., USA) and normal-
ized to β-actin.
Measurement of cytokine production by THP-1 cells
Cell culture medium and plasma samples were collected
to measure TNF-α and IL-6 by ELISA according to
manufacturer’s instructions (R&D Technologies, USA).
Statistical analysis
All values were expressed as mean ± standard error of
the mean (SEM) from 5 or 6 repetitions per group for
the cell culture and animal studies. Statistical analyses
were performed using GraphPad InStat Software. Com-
parisons among experimental groups were performed by
analysis of variance ONE-WAY ANOVA and Tukey’s test
was used as post hoc test to compare individual groups. A
p-value less than 0.05 were considered significant.
Results
H2S modulates the production of IL-6 and TNF-α in a
THP-1 model of LPS tolerance
We first investigated the amount of IL-6 and TNF-α re-
leased into the medium of cultured THP-1 cells treated
with various combination of LPS (Figs. 4 and 5). Cells
exposed initially to low concentration of LPS followed
by high concentration of LPS (Tolerance and Direct
Challenge: Group TD) produced significant less IL-6
(Fig. 4b) and TNF-α (Fig. 5b) than the amount of the
cytokines produced in the Direct Challenge Group
(Group D), validating the development of tolerance in
our experimental protocol. Similarly, a pattern of toler-
ance was noted for TNF-α production in the shorter
exposure protocol (shown in Fig. 1a) involving exposure
to 4 h of the lower concentration of LPS, followed by
4 h of the higher concentration of LPS (Fig. 5a). Surpris-
ingly, at the same time, in this shorter tolerization/expos-
ure protocol, when evaluating IL-6 production, a pattern
of additive cytokine production was seen: the amount of
cytokines produced in the TD group was higher than the
cytokines produced either by the T group or the D group
(Fig. 4a).
Next, we investigated effect of inhibition of endogen-
ous H2S generation (using AOAA) or the effect H2S do-
nation (using NaHS) on the responses characterized in
the prior section. For H2S biosynthesis inhibition AOAA
was selected, because it is an inhibitor of two major H2S
generating enzymes: cystathionine-β-synthase (CBS) and
cystathionine-γ-lyase (CSE) [26]. We did not observe
any significant effect of AOAA on the production of IL-
6 and TNF-α, either in the 4 + 4 and 24 + 24 h protocols
(Figs. 4 and 5). However, pretreatment of the cells with
NaHS significantly reduced the effect of LPS in all ex-
perimental groups (Figs. 4 and 5). The most pronounced
effect of NaHS was noted on the production of IL-6 and
TNF-α at 24 h in Group “T” (Figs. 4b and 5b) suggesting
that the inhibitory effect of H2S on cytokine production
is most pronounced when the longest time is given to
exert its effect (in this case, cytokines were measured at
48 h relative to the exposure to NaHS and to 0.5 μg/ml
LPS, as compared to the other groups, where the mea-
surements of cytokines were conducted at 24 h after ex-
posure to NaHS and LPS). One may also describe the
Fig. 2 Cell viability in an in vitro model of tolerance and sepsis.
Macrophages were stimulated either with a single dose of LPS 0.5 μg/
ml followed by a higher dose of LPS (1 μg/ml) (TD group) or directly
with LPS (1 μg/ml) (D group). The MTT assay was performed in the
experimental design described in the Fig. 1b (48 h after the start of
the experiment)
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observed effect of NaHS as follows: in the 48-h protocol
it enhanced the tolerance-inducing effect of LPS on
TNF-α and IL-6 production.
H2S modulates acetylation of histones 3 and 4 in a THP-1
model of LPS tolerance
Chromatin remodeling is a hallmark of alterations in gene ex-
pression, and changes in histone acetylation constitute a key
component of this response. We have recently demonstrated
that H2S can modulate gene expression and cytokine produc-
tion through the modulation of chromatin remodeling in acti-
vated macrophages in vitro [27] Therefore, next, we tested
whether the changes in expression of IL-6 and TNF-α shown
in Figs. 4 and 5 are associated with chromatin remodeling,
and whether H2S inhibition or H2S donation modulates these
responses in the context of LPS tolerance. We observed a
reduced acetylation of both histones 3 and 4 in cells exposed
to the higher concentration of LPS in the shorter (4 + 4 h)
LPS tolerance protocol (Fig. 6a) and of H4 in the longer
(24 + 24 h) protocol (Fig. 7b). AOAA, the inhibitor of en-
dogenous H2S production, reduced histone acetylation in the
shorter-term (4 + 4 h) tolerance protocol in all four experi-
mental groups, but did not affect histone acetylation in the
longer-term (24 + 24 h) protocol. In contrast, treatment of
the cells with the H2S donor increased acetylation of H3 and
H4, both in the shorter and the longer-term LPS tolerance
protocols, with the effect being less pronounced in the “TD”
group compared to the “T” or “D” groups (Figs. 6 and 7). In
summary, histone acetylation was enhanced in the presence
of H2S donor, an effect, which partially correlated with the in-
hibitory effect of the H2S donor on the production of IL-6
and TNF-α in the same experimental protocol.
Fig. 3 Scheme showing the administration of AOAA and NaHS in the in vitro protocol. Part (a) depicts the shorter experimental design (4 h of low
concentration of LPS exposure, followed by 4 h of high concentration of LPS exposure, followed by the collection of culture supernatant at 8 h) and
part (b) depicts the longer experimental design (24 h of low concentration of LPS exposure, followed by 24 h of high concentration of LPS exposure,
followed by the collection of culture supernatant at 48 h)
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LPS-induced production of IL-6 and TNF-α is reduced in
CSE-deficient mice during endotoxin tolerance
Next, we compared the production of IL-6 and TNF-α
in a mouse model of LPS tolerance in wild-type (WT)
and CSE knockout (CSE-/-) mice. To induce tolerance,
animals were treated with a low dose (0.5 mg/kg/day)
of LPS, followed by a single high dose (10 mg/kg) of
LPS (animal group “TD”). Another group of animals
was directly challenged with the high dose (10 mg/kg)
of LPS (animal group “D”) without any (tolerizing) pre-
treatment of a lower dose of LPS. Similar to the in vitro
studies, we have used shorter-term and longer-term
protocols; in one protocol the time of tolerizing and
challenge was both 4 h and 4 h (Figs. 8a and 9a); in
another protocol, the time of tolerizing, as well as the
time of high-dose LPS challenge was both 12-12 h
(Figs. 8b and 9b). In the shorter-term protocol, toler-
ance developed with respect to TNF-α production
(Fig. 9a), but - similar to our findings with the shorter
in vitro LPS tolerance protocol - it did develop not with
respect to IL-6 production (Fig. 8a), while in the
longer-term protocol, both mediators exhibited the
Fig. 4 H2S modulates the production of IL-6 in THP-1 cells treated with LPS. Macrophages were stimulated either with a single dose of LPS 0.5 μg/ml
(T group), a single dose of LPS 0.5 μg/ml followed by a higher dose of LPS (1 μg/ml) (TD group) or directly with LPS (1 μg/ml) (D group). IL-6 concentration
in the culture medium was measured after 4 h (a) or 24 h (b) after the final LPS treatment. The H2S biosynthesis inhibitor AOAA and the H2S donor were
both applied at 1 mM. *p< 0.05 TD vs. D groups; #p< 0.05 shows the inhibitory effect of NaHS, compared to the respective group that did not receive the
H2S donor
Fig. 5 H2S modulates expression of TNF-α in THP-1 cells treated with LPS. Macrophages were stimulated either with a single dose of LPS 0.5 μg/ml
(T group), a single dose of LPS 0.5 μg/ml followed by a higher dose of LPS (1 μg/ml) (TD group) or directly with LPS (1 μg/ml) (D group).
TNF-α concentration in the culture medium was measured after 4 h (a) or 24 h (b) after the final LPS treatment. The H2S biosynthesis inhibitor
AOAA and the H2S donor were both applied at 1 mM. *p < 0.05 TD vs. D groups; #p < 0.05 shows the inhibitory effect of NaHS, compared to
the respective group that did not receive the H2S donor
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Fig. 6 Acetylation of histone 3 is enhanced in cells treated with H2S. Macrophages were stimulated either with a single dose of LPS 0.5 μg/ml (T group),
a single dose of LPS 0.5 μg/ml followed by a higher dose of LPS (1 μg/ml) (TD group) or directly with LPS (1 μg/ml) (D group). Histone acetylation was
measured at 4 (a) or 24 (b) hours. The H2S biosynthesis inhibitor AOAA and the H2S donor were both applied at 1 mM. *p< 0.05 TD vs. D groups; #p <
0.05 shows the inhibitory effect of AOAA, or the stimulatory effect of NaHS, compared to the respective group that did not receive any treatment with
H2S modulators. From each experimental group, 3 samples were loaded on the Western blot gels, and the westerns were repeated 2 times. Bar values
represent the mean ± SEM of the actin-corrected densitometry values. Western blot insets above the bars show representative acetylated H3 histone and
actin bands
Fig. 7 Acetylation of histone 4 is enhanced in cells treated with H2S. Macrophages were stimulated either with a single dose of LPS 0.5 μg/ml
(T group), a single dose of LPS 0.5 μg/ml followed by a higher dose of LPS (1 μg/ml) (TD group) or directly with LPS (1 μg/ml) (D group). Histone
acetylation was measured at 4 (a) or 24 (b) hours. The H2S biosynthesis inhibitor AOAA and the H2S donor were both applied at 1 mM. *p < 0.05
TD vs. D groups; #p < 0.05 shows the inhibitory effect of AOAA, or the stimulatory effect of NaHS, compared to the respective group that did not
receive any treatment with H2S modulators. From each experimental group, 3 samples were loaded on the Western blot gels, and the westerns
were repeated 2 times. Bar values represent the mean ± SEM of the actin-corrected densitometry values. Western blot insets above the bars show
representative acetylated H4 histone and actin bands
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expected tolerance phenomenon, i.e. the LPS-induced
mediator production was significantly lower in the
“TD” group when compared to the “D” group (Figs. 8b
and 9b). CSE deficiency failed the affect the overall pat-
tern of these responses; LPS tolerance continued to de-
velop in the CSE-/- mice; the main difference that we
have observed between wild-type and CSE-/- mice was
that the LPS-induced cytokine responses were less pro-
nounced in the “TD” group than in the “D” group in
the longer-term protocol (Figs. 8b and 9b) and, in the
case of TNF-α production, both in the shorter-term
and the longer-term protocols (Fig. 8a).
Discussion
Gene expression programs in response to microbes re-
quires highly precise regulatory mechanisms in innate
immune system cells. LPS tolerance is a well-known
phenomenon that reduces cytokine release and inflamma-
tion, where the conditioning of the genes is dependent on
modification of histones, and this is associated with select-
ive reprogramming of several genes [8–11]. It has been
shown that two categories of chromatin modifications
induced by tolerance: one class associated with silencing
of pro-inflammatory genes and a second class, associated
with antimicrobial effectors [11].
Fig. 8 Production of IL-6 in the plasma of LPS-treated wild-type and CSE-/- mice during LPS tolerance. C57/J6 black wild type and CSE-/- mice were
randomized into the following groups: C group: vehicle treatment; TD group: 1 mg/kg LPS during 3 days, followed by the induction of endotoxemia
with 10 mg/kg LPS; D group: vehicle (instead of the tolerizing doses of LPS) before the challenge with 10 mg/kg LPS. Animals were euthanized at 4 (a)
or 12 (b) hours after exposure to 10 mg/kg LPS. *p < 0.05 TD vs. D groups; #p < 0.05 shows the inhibitory effect of CSE deficiency, compared to the
respective wild-type group
Fig. 9 Production of TNF-α in the plasma of LPS-treated wild-type and CSE-/- mice during LPS tolerance. C57/J6 black wild type and CSE-/- mice
were randomized into the following groups: C group: vehicle treatment; TD group: 1 mg/kg LPS during 3 days, followed by the induction of
endotoxemia with 10 mg/kg LPS; D group: vehicle (instead of the tolerizing doses of LPS) before the challenge with 10 mg/kg LPS. Animals
were euthanized at 4 (a) or 12 (b) hours after exposure to 10 mg/kg LPS. *p < 0.05 TD vs. D groups; #p < 0.05 shows the inhibitory effect of
CSE deficiency, compared to the respective wild-type group
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The early stimulus with lower dose of LPS initiates a
complex response of “cell reprograming”, a process that
involve, among many factors, epigenetic regulatory pro-
cesses, including histone acetylation. Prior literature
shows a promoter-specific NF-κB recruitment and his-
tone acetylation in the context of multiple LPS-mediated
pro-inflammatory and anti-microbial genes [13]. An-
other body of prior work suggests that LPS tolerance
produces an epigenetic regulation that is locus-specific
through the delimitation of the acetylation [11].
Our results confirmed that induction of LPS tolerance
decreases the production of the pro-inflammatory cyto-
kines TNF-α and IL-6 in vitro [8, 10, 27]. Our data also
confirm that tolerance induction reduces cytokine pro-
duction in an in vivo model of sepsis, especially in the
longer-term protocol employed. We have also demon-
strated that LPS tolerance is associated with marked
changes in histone acetylation, although in a rather com-
plex pattern, which does not always or directly mirror
the observed changes in cytokine production. In other
words, the changes in the acetylation of histones during
the development of LPS tolerance (as well as in response
to the subsequent high-dose LPS challenge) are dynamic
and histone-specific. The most consistent pattern that
was observed was that the increases in cytokine produc-
tion in response LPS tend to be associated with reduced
histone acetylation, and tolerance tends to increase/re-
verse these alterations in histone acetylation, while also
suppressing cytokine production. This is also consistent
with prior reports indicating that during LPS tolerance,
histone acetylation contributes to the silencing of pro-
inflammatory gene transcription [28–32]. Moreover, our
group demonstrated an association between the reduc-
tion of cytokine release and the decrease on histone H3
acetylation at the IL-6 and TNF-α promoters in the cell
exposed to H2S or H2S + LPS [27].
As far as the effect of H2S modulation, in the cell-
based model, the most consistent and most pronounced
finding was that the H2S donor markedly reduced pro-
inflammatory cytokine production, and these effects
tended to coincide with marked increases in histone
acetylation. These findings continue to be consistent
with the patterns seem in our in vitro experimental sys-
tem, whereby - generally - higher histone acetylation
corresponds to lower cytokine production, while lower
histone acetylation corresponds to higher cytokine pro-
duction. However, these patterns are not universally ap-
plicable. For instance, in the short-term protocol, the
changes in TNF-α production do not correspond with
the changes in IL-6 production, even though, obviously,
the histone acetylation patterns (at least, on the macro-
scale of total H3 and H4 acetylation) are the comparable.
Moreover, the inhibitory effect of the CBS/CSE inhibitor
AOAA on histone acetylation (although it does mirror
the stimulatory effect of H2S donor on histone acetyl-
ation) did not manifest in any detectable change in LPS-
induced cytokine production. Clearly, histone acetylation
is only one of many pathways induced by LPS and/or
affected by H2S biosynthesis modulation, and the net
results (such as cytokine production and the develop-
ment of tolerance) are the result of a whole host of
interacting factors, only some of which have been inves-
tigated here.
When designing the current set of experiments, our
working hypothesis was that H2S production may be a
contributing factor in the development of LPS tolerance.
However, the results did not support this hypothesis; the
phenomenon of LPS tolerance has developed regardless
whether H2S production was attenuated (by pretreating
the cells with AOAA), or when H2S levels were en-
hanced (by pretreating the cells with the H2S donor
NaHS). The presence of the H2S donor appeared to
potentiate the effect of tolerance (resulting in very low
cytokine levels in the “TD” group in the longer-term
experimental protocols), perhaps indicative that the anti-
inflammatory pathways that tolerance induces and the
anti-inflammatory pathways that H2S induces are addi-
tive or synergistic.
However, the in vivo studies of LPS tolerance are not
consistent with the conclusions made in the in vitro
model: based on the effects of H2S in the in vitro model
(where H2S suppresses cytokine production and enhances
the anti-inflammatory effect of tolerance), we expected
that CSE-/- mice (that have reduced H2S levels) would
respond with higher cytokine production or a lesser
degree of tolerization; however, the data showed that
tolerance developed in CSE-/- mice the same way as in
wild-type mice, and, in fact, the amount of cytokines pro-
duced in response to high-dose LPS was lower than in
wild-type mice.
The current paper has several limitations. For instance,
using CSE-/- mice, one can only probe one source of H2S
(the one produced by CSE). CSE-/- mice have lower levels
of circulating H2S, but, nevertheless, circulating H2S levels
are still detectable [33]. Other components of the circulat-
ing H2S levels (i.e. H2S produced by cystathionine-β-
synthase [CBS] or 3-mercaptopyruvate sulfurtransferase
[3-MST] remain to be investigated in future studies).
Another weakness of the current study is that we have
only utilized one type of H2S source, the salt NaHS. This
compound generates high levels of H2S in the tissue
culture medium, which, then decreases over time due to a
combination of cellular metabolism and physical processes
(outgassing from the culture medium) [34, 35]. Follow-up
studies may use H2S donors with longer half-life (e.g. the
compound GYY4137) [35, 36] or with H2S donors that
are targeting H2S to various cellular compartments (e.g.
the mitochondrially targeted H2S donor AP39) [37].
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Conclusions
Taken together, the current findings are consistent with
several lines of independent observations [8–13, 18, 28–
32, 38, 39] showing or suggesting that histone acetyl-
ation is modulated during LPS tolerance development,
and suggest that histone acetylation may, at least in part,
contribute to LPS tolerance. The findings also confirm
prior observations [27, 40–44] showing that H2S donors
can suppress LPS-induced cytokine production in vitro.
In contrast, in vivo, LPS-induced H2S production is
lower in the CSE-/- mice (which exhibit lower circulating
levels of H2S) [33], suggesting that in this model - as
opposed to the results of our in vitro experiments where
inhibition of endogenous H2S production did not affect
cytokine production - endogenously produced H2S en-
hances systemic cytokine production. Finally, the pres-
ence or absence of H2S does not appear to play a major
role in the development of LPS tolerance in the in vitro
and in vivo models used in the current study.
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